LOVELY INSTITUTE OF MANAGEMENT

DEPARTMENT OF MANAGEMENT

(3RD ) ASSIGNMENT

OF

ORGANISATION CHANGE AND DEVELOPMENT

ON

SUCCESS AND FAILURE OF OD PRACTIONER IN THE ORGANISATIONS

INTRODUCTION OF THE COMPANY:

(GLAXO SMITH KLINE)

GlaxoSmithKline, often abbreviated to GSK, is a global pharmaceutical, biologics, vaccines and

consumer healthcare company headquartered in London, United Kingdom. It is the world's third
largest pharmaceutical company measured by revenues (after Johnson & Johnson and Pfizer). It
has a portfolio of products for major disease areas including asthma, cancer, virus control,
infections, mental health, diabetes and digestive conditions. It also has a large consumer
healthcare division which produces and markets oral healthcare products, nutritional drinks and
over-the-counter medicines, including Sensodyne, Horlicks and Gaviscon.Its primary listing is
on the London Stock Exchange and it is a constituent of the FTSE 100 Index. It has a secondary
listing on the New York Stock Exchange.

GSK was formed in 2000 by the merger of GlaxoWellcome plc (formed from the acquisition of
Wellcome plc by Glaxo plc), and SmithKline Beecham plc (from the merger of Beecham plc, and
SmithKlineBeckman Corporation). In 1880, Burroughs Wellcome & Company was founded in
London by American pharmacists Henry Wellcome and Silas Burroughs. The Wellcome Tropical
Research Laboratories opened in 1902. In 1959 the Wellcome Company bought Cooper,
McDougall & Robertson Inc. to become more active in animal health.The Wellcome Company
production centre was moved from New York to North Carolina in 1970 and the following year
another research centre was built.

Glaxo was founded in Bunnythorpe, New Zealand in 1904. Originally Glaxo was a baby food
manufacturer processing local milk into a baby food by the same name: the product was sold in
the 1930s under the slogan "Glaxo builds bonny babies". Still visible on the main street of
Bunnythorpe is a derelict dairy factory (factory for drying and processing cows' milk into
powder) with the original Glaxo logo clearly visible, but nothing to indicate that this was the
start of a major multinational company.
Glaxo became Glaxo Laboratories, and opened new units in London in 1935. Glaxo
Laboratories bought two companies, Joseph Nathan and Allen & Hanburys, in 1947 and 1958
respectively.After the Company bought Meyer Laboratories in 1978,it started to play an
important role in the US market. In 1983 the American arm Glaxo Inc. moved to Research
Triangle Park (US headquarters/research) and Zebulon (US manufacturing) in North Carolina.
Burroughs Wellcome and Glaxo merged in 1995 to form GlaxoWellcome.In the same year,
GlaxoWellcome opened its Medicine Research Centre in Stevenage. Three years later
GlaxoWellcome bought Polfa Poznan Company in Poland.

Operations:

As the second largest pharmaceutical company in the world, based on net income, the company
had sales of £22.7 billion and made a profit of £7.8 billion in 2007. It employs over 90,000
people worldwide, according to GSK website, including over 40,000 in sales and marketing. Its
global headquarters are GSK House in Brentford, London, United Kingdom, with its United
States headquarters based in Research Triangle Park (RTP) in North Carolinaand its consumer
products division based in the Pittsburgh suburb of Moon Township, Pennsylvania. The research
and development division has major headquarters in South East England, Philadelphia and
Research Triangle Park (RTP) in North Carolina.

The company's stock is listed on the London stock exchange and ADRs are listed on the NYSE.
The single largest market is in the United States (approximately 45% of revenue), although the
company has a presence in almost 70 countries.

In November 2009 GlaxoSmithKline formed a joint venture with Pfizer to create ViiV
Healthcare. Viiv Healthcare received all of Pfizer and GlaxoSmithKline's HIV assets.ViiV
Healthcare is 85% owned by GlaxoSmithKline and 15% owned by Pfizer.

Recent developments:

In 2001 it completed its purchase of New Jersey-based Block Drug.

On November 16, 2009 the US Food and Drug Administration (FDA) announced that a vaccine
for 2009 H1N1 influenza protection (manufactured by GSK's ID Biomedical Corp. subsidiary)
would join the four vaccines approved on September 15.

In June 2010, the company acquired Laboratorios Phoenix, an Argentine pharmaceutical

company focused on the development, marketing and sale of branded generic products, for a
cash consideration of approximately $253m.

In December 2010, GSK announced its acquisition of the sports nutrition company
Maxinutrition
Initiatives to eradicate disease:

Glaxo SmithKline has been active in a global alliance to eliminate lymphatic filariasis. Jean-
Pierre (JP) Garnier, former CEO of GlaxoSmithKline has said, “The Egyptian data shows that
we can now eliminate a disease that has plagued the world for centuries. We remain committed
to donating as much albendazole as required to eliminate this disabling disease, but ultimate
success will depend on continued long-term commitments by all partners across the globe.”

In addition Glaxo has been short-listed for awards such as the Worldaware Business Award for
its work to eliminate malaria in Kenya. GlaxoSmithKline recently donated money to the British
flood appeal, and was ranked first on the 2006 UK Corporate Citizenship Index for donations

Corporate governance:

Current members of the board of directors of GlaxoSmithKline are:

• Sir Christopher Gent (Non-Executive Chairman);

• Andrew Witty (Chief Executive Officer, Executive Director);
• Dr Stephanie Burns (Non-Executive Director);
• Lawrence Culp (Non-Executive Director);
• Sir Crispin Davis (Non-Executive Director);
• Julian Spenser Heslop (Chief Financial Officer, Executive Director);
• Sir Deryck Maughan (Non-Executive Director);
• Sir Ian Prosser (Senior Independent Non-Executive Director);
• Dr Ronaldo Schmitz (Non-Executive Director);
• Moncef Slaoui (Chairman, Executive Director, Research & Development);
• Robert Wilson (Non-Executive Director);
• Dr Daniel Podolsky (Non-Executive Director);
• Tom De Swaan (Independent Non-Executive Director);
• Marc Dunoyer (President, Pharmaceuticals Asia Pacific/Japan);
• David Pulman Ph.D. (President - Global Manufacturing and Supply);
• John Clarke (President - Consumer Healthcare);
• Emma Walmsley (President - Consumer Healthcare Europe);
• Eddie Gray (President, Pharmaceuticals Europe);
• Abbas Hussain (President - Emerging Markets);
• Roberto C. Taboada (President and Managing Director of Philippine);
• Deirdre P. Connelly (President, North American Pharmaceuticals);
• James Murdoch (Non-Executive Director).

On October 8, 2007 it was announced that Dr Garnier would be succeeded as Chief Executive
by Mr Andrew Witty. Mr Witty, 44, has taken up the position in May 2008 and joined the Board.
Although job losses have been widespread in the company, Mr Witty himself has seen his pay
increase by 76% over the last year.

INTRODUCTION OF COMPANY:
(CADILA PHARMACEUTICAL LTD)

The Care Continues...

Cadila Pharmaceuticals Ltd. is one of Indias most reputed, Research based, Tech savvy
pharmaceutical companies focusing on areas – Formulations (Human & Veterinary),
New Drug Discovery, Novel Drug Delivery, Active Pharmaceutical Ingredients,
Analytical Research, Photochemistry, Biotechnology, Plant Tissue Culture, Biosynthesis,
Genetic Engineering, Vaccines, Immunoglobulin’s – the entire gamut of a True Life
Sciences Company.

'Cadila Healthcare' is an Indian pharmaceutical company head quartered at Ahmadabad in

Gujarat state of western India. The company is the fifth largest pharmaceutical company in
India with US$290m in turnover in 2004. It is a significant manufacturer of generic drugs.
Cadila Pharma have developed a drug named Roserin which has reduced the cost of curing TB
by 33%.
History:

Cadila Laboratories was founded in 1952 by Ramanbhai Patel (1925-2001), formerly a lecturer
in the L.M. College of Pharmacy, and his business partner Shri Indravadan Modi. The
company evolved over the next four decades into one of India's established pharmaceutical
companies.

In 1995 the Patel and Modi families split, with the Modi family's share being moved into a new
company called Cadila Pharmaceuticals Ltd. and Cadila Healthcare became the Patel family's
holding company. Cadila Healthcare did its IPO on the Bombay Stock Exchange in 2000. Its
stock code on the Bombay exchange is 532321.

In 2001 the company acquired another Indian pharmaceutical company called German
Remedies. On June 25, 2007, the company signed an agreement to acquire 100 per cent stake in
Brazils Quimica e Farmaceutica Nikkho do Brasil Ltda (Nikkho) for around 26 million dollars.

general information about firm:

Cadila Pharmaceutical Limited is one of the leading pharmaceutical companies in India. Cadila
has plant at multiple locations in, India. Cadila Laboratories Limited was established in the year
1951 and over the last 55 year has made progress by leaps and bounds and is,as on today a
leading Pharmaceutical Company in the area of health care. Cadila has diversified into
formulations, bulk drugs, hospital products, tissue culture products diagnostics, veterinary
products, and biotechnology products, pharmaceutical machinery, manufacturing etc.

Restructing of Cadila laboratories limited took place in june 1995 and in the process Cadila
pharmaceuticals limited was formed. Cadilla has set up a state of the art pharmaceutical dosage
manufacturing facility at Samba,near jammu.This manufacturing facility produces various
formulations viz,tablets,capsules and oral liquids.

Mr. Indravadn A.Modi is one of the founder directors of Cadilla Group and the chairman of
Cadila pharmaceutical limited acknowledged by the Indian Pharmaceutical Industry as a
veteran Pharmaceutical Entrepreneur, together with Dr.Rajiv I.Modi (Managing Director)
,cellular molecular biologist from the university of Michigan,U.S.A,is the guiding force for
Cadila pharmaceuticals Ltd.

Cadila Pharmaceutical Ltd has got the distinction of being approved for the manufacture of
World’s first drug against Leprosy cadila pharmaceutical Ltd established the quality of its
product right at developmental stage with strong support of its R and D centre which is very
equipped and more than 100 scientists of various disciplines are working. Cadila
Pharmaceutical made its presence and recognition globally in the post-GATT scenario.

company vision:
The company’s vision is to be a leading pharmaceutical company in India and to become a
significant global player by providing high quality , affordable and innovative solutions in
medicine.

company mission:
We will discover , develop and successfully market pharmaceutical products to prevent,
diagnose, alleviate and cure diseases.

We shall provide total customer satisfaction and achieve leadership in chosen market , products
and services across the globe , through excellence in technology based on world class research
and development .

We are responsible to the society , we shall be good corporate citizens and will be driven by
high ethical standards in our practices.

quality policy:
“We are in the business of design , development , manufacturing and supply of pharmaceuticals
formulation of national and international pharmaceutical standards/ customers specification to
meet the requirements of customers and enhance their satisfaction”. This shall be achieved by:

 Establishing and continually improving the effectiveness of the processes relating to

quality management system .

 Provision of resources and

 Compliance to applicable regulation.

CAUSES OF SUCCESS AND FAILURE IN EACH ORGANIZATION:

ROLE OF ORGANISATION DEVELOPMENT PRACTIONER IN AN ORGANISATION:

OD practioner plays an important role in the organization. It helps to improve the effectiveness
of the organization. When the organization finds that their is a need of some changes at that time
the organization decides for an OD practioner. OD practioner can be a internal practioner or
an external practioner who are the speaclists in the field of OD and related areas.

OD practioners skills:

• Leadership quality

• Project management

• Communication

• Problem solving

• Interpersonal skills

• Personal skills

SUCCEES OF OD PRACTIONER IN CADILA PHARMACEUTICAL:

As we know Cadila pharmaceutical is one of the leading company in pharma sector. In cadila
there are 7 departments are as

• Quality assurance

• Quality control

• Engeneering

• Human resource
 • Admin and hospitality

• Hospicon

• Softgel

These are the different departments and when the company find that their machinery and
equipments that are used in the production are very old. And that time they realized that their
should be change in that and they decided to consult it with the OD practioner. Then they call an
OD practioner who are the internal.

Cadila’s OD practioner was the internal practioner who was familiar with the organization.
The condition before the OD practioner was:

• Low productivity

• Low profit

• Wastage of raw material

• Low working efficiency

• Very long operating cycle

• Employees are unable to change

• Low employees morale

• Very high attrition rate

After OD practioner:

• High productivity

• High profit

• Optimum use of resources

• Optimum operating cycle

• Employees readiness to accept changes

• High morale
 • High retention rate

These are the positive results after introducing an OD practioner in cadila pharmaceutica ltd.
Why this leads to the success because the OD practioner was familiar with the organization.
Wher they bring change is in the machinery and production line that is known as DEXA LINE
in cadila pharmaceutical. In this line there are 5 phases an every phase is the combination of
innovative technology and equipments. In this every tablet or product goes within the 5 phases
that helps to increase the quality and increase in the work efficiency of the worker.

FAILURE OF OD PRACTIONER IN GSK:

GSK is also one one of the largest pharmaceutical company.this company is well known for their
technologies. They have innovative technologies and forward machines.

When GSK bring a change in their mission as well as vision most of the employees were against
with that change because they feel that every thing is going on very right pace. But company
bring change and decided to bring an OD practioner from outside. In this organization they call
the same practioner who were in the cadila because both companies are in the same sector.

Position of GSK before change:

• Innovative technologies

• High job satisfaction and employees morale

• High productivity

• Maximum profit

Postion after change:

• Change in vision and mission leads to controversy

• Decrease in production
 • High attrition rate

• High switchover cost

• Low job satisfaction

This was the condition after the change and the consultation of the OD practioner. These were
the results because the OD practioner was external and he was unable to understand the current
situation. The was in the growing pace but after change it camedown. The reasons of fliur was
the lack of knowledge about the company as well as their employees.

SUGGESTIONS:
• OD practioner should have proper knowledge about the organization.

• OD practioner should have information: why the organization is going for change?

When change should be implement?

Where it should be implement?

• Most probably the practioner should be internal practioner.

• OD practioner should do preliminary survey.

• OD practioner should be specialist in related areas.

• OD practioner should have influencing power so that employees can easily accept the
changes.

• They also have project management skills so that they can easily handle difficult tasks;
 • They also have problem solving power so they can solve the personal as well as wok
related problem of employees.

CONCLUSION:
The role of the OD consultant is complex, requires a wide range of knowledge and skills, and
typically requires experience in the organisational world. The skills discussed in this article, are
the basic skills that every OD practitioner should have. However, specific interventions might
require specialised skills, e.g. an intervention in improving work design in an Aluminium
Factory is likely to benefit from an OD consultant who is familiar with the manufacturing
environment, as opposed to one who has mostly worked in the Financial Services
environment. The OD practitioner should participate in the process of selecting, or not selecting
himself, by guiding the client to understand these issues.

REFERENCES:

http://www.google.co.in/webhp?
hl=en#hl=en&biw=1276&bih=593&q=role+of+OD+practioner+in+organisation&aq=o&aqi
=&aql=&oq=&fp=d2d7c6a1e0c3a4b4

http://www.google.co.in/webhp?
hl=en#hl=en&source=hp&biw=1276&bih=593&q=logo+of+GSK&aq=f&aqi=&aql=&oq=&
fp=d2d7c6a1e0c3a4b4

http://www.google.co.in/webhp?
hl=en#hl=en&source=hp&biw=1276&bih=593&q=cadilapharmaceutical&aq=o&aqi=&aql=
&oq=&fp=d2d7c6a1e0c3a4b4

http://www.google.co.in/#q=introduction+of+glaxo+smith&hl=en&biw=1276&bih=593&prm
d=ivns&ei=ATyITcX6E4PYrQe5k_DdDg&start=10&sa=N&fp=d2d7c6a1e0c3a4b4